CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: cirrhotic patients</title> <meta name="description" content="Search results for: cirrhotic patients"> <meta name="keywords" content="cirrhotic patients"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="cirrhotic patients" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="cirrhotic patients"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 5588</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: cirrhotic patients</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5588</span> Propranalol is Not Effective in Preventing the Progression to Severe Portal Hypertensive Gastropathy in Cirrhotic Patients who Had Undergone Variceal Eradication: A Randomised Controlled Trial</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Jeffey%20George">Jeffey George</a>, <a href="https://publications.waset.org/abstracts/search?q=Varghese%20Thomas"> Varghese Thomas</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Objectives: PHG is an important source of gastrointestinal bleeding in patients with portal hypertension. Aim: To assess the progression to severe portal hypertensive gastropathy(PHG) in patients with cirrhosis who were treated with maximum tolerated dose of propranalol, after variceal eradication to grade II or below. Methods: Cirrhotic patients(child A and B) presenting with upper gastrointestinal bleeding with endoscopic findings of mild or no PHG were followed up over 6 months after variceal eradication to assess the progression to severe PHG. Included patients were randomised to either maximum tolerated doses of propranalol (group A) or to no treatment (group B). Primary end point of the study were the development of gastrointestinal bleed, evidence of hepatic decompensation and death. Progression to severe PHG were compared between the two groups. Results: 56 patients (49 males) were enrolled (group A = 28, group B = 28). 8 patients were excluded from final analysis (gi bleed=5, encephalopathy=2,HCC=1 including 4 deaths).3 patients were lost to follow-up, and 1 developed intolerance to propranalol. Mean dose of propranalol used was 60 mg per day. Progression to severe PHG in the fundus over 6 months was 23.8% in group A versus 15.8 % in group B (p = 0.52). Severe PHG was noted in body in 14.3% in group A versus 21.1% in group B (p = 0.57). 23.8 % in group A had progression to severe PHG compared with 15.8 % in group B (p =0.52). There was no statistically significant difference in the progression of PHG between the two groups(p=0.43). Conclusion: In this short term study propranalol was found not to prevent the progression to severe portal hypertensive gastropathy in cirrhotic patients who had undergone endotherapy for esophageal varices. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=propranalol" title="propranalol">propranalol</a>, <a href="https://publications.waset.org/abstracts/search?q=portal%20hypertensive%20gastropathy" title=" portal hypertensive gastropathy"> portal hypertensive gastropathy</a>, <a href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients" title=" cirrhotic patients"> cirrhotic patients</a>, <a href="https://publications.waset.org/abstracts/search?q=gastroenterology" title=" gastroenterology"> gastroenterology</a> </p> <a href="https://publications.waset.org/abstracts/14748/propranalol-is-not-effective-in-preventing-the-progression-to-severe-portal-hypertensive-gastropathy-in-cirrhotic-patients-who-had-undergone-variceal-eradication-a-randomised-controlled-trial" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/14748.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">346</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5587</span> Qualitative Detection of HCV and GBV-C Co-infection in Cirrhotic Patients Using a SYBR Green Multiplex Real Time RT-PCR Technique</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shahzamani%20Kiana">Shahzamani Kiana</a>, <a href="https://publications.waset.org/abstracts/search?q=Esmaeil%20Lashgarian%20Hamed"> Esmaeil Lashgarian Hamed</a>, <a href="https://publications.waset.org/abstracts/search?q=Merat%20Shahin"> Merat Shahin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> HCV and GBV-C belong to the Flaviviridae family of viruses and GBV-C is the closest virus to HCV genetically. Accumulative research is in progress all over the world to clarify clinical aspects of GBV-C. Possibility of interaction between HCV and GBV-C and also its consequence with other liver diseases are the most important clinical aspects which encourage researchers to develop a technique for simultaneous detection of these viruses. In this study a SYBR Green multiplex real time RT-PCR technique as a new economical and sensitive method was optimized for simultaneous detection of HCV/GBV-C in HCV positive plasma samples. After designing and selection of two pairs of specific primers for HCV and GBV-C, SYBR Green Real time RT-PCR technique optimization was performed separately for each virus. Establishment of multiplex PCR was the next step. Finally our technique was performed on positive and negative plasma samples. 89 cirrhotic HCV positive plasma samples (29 of genotype 3 a and 27 of genotype 1a) were collected from patients before receiving treatment. 14% of genotype 3a and 17.1% of genotype 1a showed HCV/GBV-C co-infection. As a result, 13.48% of 89 samples had HCV/GBV-C co-infection that was compatible with other results from all over the world. Data showed no apparent influence of HGV co-infection on the either clinical or virological aspect of HCV infection. Furthermore, with application of multiplex Real time RT-PCR technique, more time and cost could be saved in clinical-research settings. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HCV" title="HCV">HCV</a>, <a href="https://publications.waset.org/abstracts/search?q=GBV-C" title=" GBV-C"> GBV-C</a>, <a href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients" title=" cirrhotic patients"> cirrhotic patients</a>, <a href="https://publications.waset.org/abstracts/search?q=multiplex%20real%20time%20RT-%20PCR" title=" multiplex real time RT- PCR"> multiplex real time RT- PCR</a> </p> <a href="https://publications.waset.org/abstracts/31403/qualitative-detection-of-hcv-and-gbv-c-co-infection-in-cirrhotic-patients-using-a-sybr-green-multiplex-real-time-rt-pcr-technique" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/31403.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">295</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5586</span> Insulin Resistance in Patients with Chronic Hepatitis C Virus Infection: Upper Egypt Experience</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ali%20Kassem">Ali Kassem</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: In the last few years, factors such as insulin resistance (IR) and hepatic steatosis have been linked to progression of hepatic fibrosis.Patients with chronic liver disease, and cirrhosis in particular, are known to be prone to IR. However, chronic HCV (hepatitis C) infection may induce IR, regardless of the presence of liver cirrhosis. Our aims are to study insulin resistance (IR) assessed by HOMA-IR (Homeostatic Model Assessment Insulin Resistance) as a possible risk factor in disease progression in cirrhotic patients and to evaluate the role of IR in hepatic fibrosis progression. The correlations of HOMA-IR values to laboratory, virological and histopathological parameters of chronic HCV are also examined. Methods: The study included 50 people divided into 30 adult chronic hepatitis C patients diagnosed by PCR (polymerase chain reaction) within previous 6 months and 20 healthy controls. The functional and morphological status of the liver were evaluated by ultrasonography and laboratory investigations including liver function tests and by liver biopsy. Fasting blood glucose and fasting insulin levels were measured and body mass index and insulin resistance were calculated. Patients having HOMA-IR >2.5 were labeled as insulin resistant. Results: Chronic hepatitis C patients with IR showed significantly higher mean values of BMI (body mass index) and fasting insulin than those without IR (P < 0.000). Patients with IR were more likely to have steatosis (p = 0.006), higher necroinflammatory activity (p = 0.05). No significant differences were found between the two groups regarding hepatic fibrosis. Conclusion: HOMA-IR measurement could represent a novel marker to identify the cirrhotic patients at greater risk for the progression of liver disease. As IR is a potentially modifiable risk factor, these findings may have important prognostic and therapeutic implications. Assessment of IR by HOMA-IR and improving insulin sensitivity are recommended in patients with HCV and related chronic liver disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatic%20fibrosis" title="hepatic fibrosis">hepatic fibrosis</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20C%20virus%20infection" title=" hepatitis C virus infection"> hepatitis C virus infection</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatic%20steatosis" title=" hepatic steatosis"> hepatic steatosis</a>, <a href="https://publications.waset.org/abstracts/search?q=insulin%20resistance" title=" insulin resistance"> insulin resistance</a> </p> <a href="https://publications.waset.org/abstracts/94698/insulin-resistance-in-patients-with-chronic-hepatitis-c-virus-infection-upper-egypt-experience" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/94698.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">154</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5585</span> Budget Impact Analysis of a Stratified Treatment Cascade for Hepatitis C Direct Acting Antiviral Treatment in an Asian Middle-Income Country through the Use of Compulsory and Voluntary Licensing Options</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Amirah%20Azzeri">Amirah Azzeri</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatiha%20H.%20Shabaruddin"> Fatiha H. Shabaruddin</a>, <a href="https://publications.waset.org/abstracts/search?q=Scott%20A.%20McDonald"> Scott A. McDonald</a>, <a href="https://publications.waset.org/abstracts/search?q=Rosmawati%20Mohamed"> Rosmawati Mohamed</a>, <a href="https://publications.waset.org/abstracts/search?q=Maznah%20Dahlui"> Maznah Dahlui</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objective: A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to Sofosbuvir/Daclatasvir (SOF/DAC) is available through compulsory licensing, with future access to Sofosbuvir/Velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements. SOF/VEL has superior clinical outcomes, particularly for cirrhotic stages, but has higher drug acquisition costs compared to SOF/DAC. It has been proposed that a stratified treatment cascade might be the most cost-efficient approach for Malaysia whereby all HCV patients are treated with SOF/DAC except for patients with cirrhosis who are treated with SOF/VEL. This study aimed to conduct a five-year budget impact analysis from the provider perspective of the proposed stratified treatment cascade for HCV treatment in Malaysia. Method: A disease progression model that was developed based on model-predicted HCV epidemiology data in Malaysia was used for the analysis, where all HCV patients in scenario A were treated with SOF/DAC for all disease stages while in scenario B, SOF/DAC was used only for non-cirrhotic patients and SOF/VEL was used for the cirrhotic patients. The model projections estimated the annual numbers of patients in care and the numbers of patients to be initiated on DAA treatment nationally. Healthcare costs associated with DAA therapy and disease stage monitoring was included to estimate the downstream cost implications. For scenario B, the estimated treatment uptake of SOF/VEL for cirrhotic patients were 25%, 50%, 75%, 100% and 100% for 2018, 2019, 2020, 2021 and 2022 respectively. Healthcare costs were estimated based on standard clinical pathways for DAA treatment described in recent guidelines. All costs were reported in US dollars (conversion rate US$1=RM4.09, the price year 2018). Scenario analysis was conducted for 5% and 10% reduction of SOF/VEL acquisition cost anticipated from the competitive market pricing of generic DAA in Malaysia. Results: The stratified treatment cascade with SOF/VEL in Scenario B was found to be cost-saving compared to Scenario A. A substantial portion of the cost reduction was due to the costs associated with DAA therapy which resulted in USD 40 thousand (year 1) to USD 443 thousand (year 5) savings annually, with cumulative savings of USD 1.1 million after 5 years. Cost reductions for disease stage monitoring were seen in year three onwards which resulted in cumulative savings of USD 1.1 thousand. Scenario analysis estimated cumulative savings of USD 1.24 to USD 1.35 million when the acquisition cost of SOF/VEL was reduced. Conclusion: A stratified treatment cascade with SOF/VEL was expected to be cost-saving and can results in a budget impact reduction in overall healthcare expenditure in Malaysia compared to treatment with SOF/DAC. The better clinical efficacy with SOF/VEL is expected to halt patients’ HCV disease progression and may reduce downstream costs of treating advanced disease stages. The findings of this analysis may be useful to inform healthcare policies for HCV treatment in Malaysia. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Malaysia" title="Malaysia">Malaysia</a>, <a href="https://publications.waset.org/abstracts/search?q=direct%20acting%20antiviral" title=" direct acting antiviral"> direct acting antiviral</a>, <a href="https://publications.waset.org/abstracts/search?q=compulsory%20licensing" title=" compulsory licensing"> compulsory licensing</a>, <a href="https://publications.waset.org/abstracts/search?q=voluntary%20licensing" title=" voluntary licensing"> voluntary licensing</a> </p> <a href="https://publications.waset.org/abstracts/100330/budget-impact-analysis-of-a-stratified-treatment-cascade-for-hepatitis-c-direct-acting-antiviral-treatment-in-an-asian-middle-income-country-through-the-use-of-compulsory-and-voluntary-licensing-options" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/100330.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">164</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5584</span> Application of Gamma Frailty Model in Survival of Liver Cirrhosis Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Elnaz%20Saeedi">Elnaz Saeedi</a>, <a href="https://publications.waset.org/abstracts/search?q=Jamileh%20Abolaghasemi"> Jamileh Abolaghasemi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohsen%20Nasiri%20Tousi"> Mohsen Nasiri Tousi</a>, <a href="https://publications.waset.org/abstracts/search?q=Saeedeh%20Khosravi"> Saeedeh Khosravi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Goals and Objectives: A typical analysis of survival data involves the modeling of time-to-event data, such as the time till death. A frailty model is a random effect model for time-to-event data, where the random effect has a multiplicative influence on the baseline hazard function. This article aims to investigate the use of gamma frailty model with concomitant variable in order to individualize the prognostic factors that influence the liver cirrhosis patients’ survival times. Methods: During the one-year study period (May 2008-May 2009), data have been used from the recorded information of patients with liver cirrhosis who were scheduled for liver transplantation and were followed up for at least seven years in Imam Khomeini Hospital in Iran. In order to determine the effective factors for cirrhotic patients’ survival in the presence of latent variables, the gamma frailty distribution has been applied. In this article, it was considering the parametric model, such as Exponential and Weibull distributions for survival time. Data analysis is performed using R software, and the error level of 0.05 was considered for all tests. Results: 305 patients with liver cirrhosis including 180 (59%) men and 125 (41%) women were studied. The age average of patients was 39.8 years. At the end of the study, 82 (26%) patients died, among them 48 (58%) were men and 34 (42%) women. The main cause of liver cirrhosis was found hepatitis 'B' with 23%, followed by cryptogenic with 22.6% were identified as the second factor. Generally, 7-year’s survival was 28.44 months, for dead patients and for censoring was 19.33 and 31.79 months, respectively. Using multi-parametric survival models of progressive and regressive, Exponential and Weibull models with regard to the gamma frailty distribution were fitted to the cirrhosis data. In both models, factors including, age, bilirubin serum, albumin serum, and encephalopathy had a significant effect on survival time of cirrhotic patients. Conclusion: To investigate the effective factors for the time of patients’ death with liver cirrhosis in the presence of latent variables, gamma frailty model with parametric distributions seems desirable. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=frailty%20model" title="frailty model">frailty model</a>, <a href="https://publications.waset.org/abstracts/search?q=latent%20variables" title=" latent variables"> latent variables</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20cirrhosis" title=" liver cirrhosis"> liver cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=parametric%20distribution" title=" parametric distribution"> parametric distribution</a> </p> <a href="https://publications.waset.org/abstracts/58300/application-of-gamma-frailty-model-in-survival-of-liver-cirrhosis-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/58300.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">261</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5583</span> Cirrhosis Mortality Prediction as Classification using Frequent Subgraph Mining</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abdolghani%20Ebrahimi">Abdolghani Ebrahimi</a>, <a href="https://publications.waset.org/abstracts/search?q=Diego%20Klabjan"> Diego Klabjan</a>, <a href="https://publications.waset.org/abstracts/search?q=Chenxi%20Ge"> Chenxi Ge</a>, <a href="https://publications.waset.org/abstracts/search?q=Daniela%20Ladner"> Daniela Ladner</a>, <a href="https://publications.waset.org/abstracts/search?q=Parker%20Stride"> Parker Stride</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this work, we use machine learning and novel data analysis techniques to predict the one-year mortality of cirrhotic patients. Data from 2,322 patients with liver cirrhosis are collected at a single medical center. Different machine learning models are applied to predict one-year mortality. A comprehensive feature space including demographic information, comorbidity, clinical procedure and laboratory tests is being analyzed. A temporal pattern mining technic called Frequent Subgraph Mining (FSM) is being used. Model for End-stage liver disease (MELD) prediction of mortality is used as a comparator. All of our models statistically significantly outperform the MELD-score model and show an average 10% improvement of the area under the curve (AUC). The FSM technic itself does not improve the model significantly, but FSM, together with a machine learning technique called an ensemble, further improves the model performance. With the abundance of data available in healthcare through electronic health records (EHR), existing predictive models can be refined to identify and treat patients at risk for higher mortality. However, due to the sparsity of the temporal information needed by FSM, the FSM model does not yield significant improvements. To the best of our knowledge, this is the first work to apply modern machine learning algorithms and data analysis methods on predicting one-year mortality of cirrhotic patients and builds a model that predicts one-year mortality significantly more accurate than the MELD score. We have also tested the potential of FSM and provided a new perspective of the importance of clinical features. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=machine%20learning" title="machine learning">machine learning</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20cirrhosis" title=" liver cirrhosis"> liver cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=subgraph%20mining" title=" subgraph mining"> subgraph mining</a>, <a href="https://publications.waset.org/abstracts/search?q=supervised%20learning" title=" supervised learning"> supervised learning</a> </p> <a href="https://publications.waset.org/abstracts/137686/cirrhosis-mortality-prediction-as-classification-using-frequent-subgraph-mining" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/137686.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">134</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5582</span> Identification of a Panel of Epigenetic Biomarkers for Early Detection of Hepatocellular Carcinoma in Blood of Individuals with Liver Cirrhosis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Katarzyna%20Lubecka">Katarzyna Lubecka</a>, <a href="https://publications.waset.org/abstracts/search?q=Kirsty%20Flower"> Kirsty Flower</a>, <a href="https://publications.waset.org/abstracts/search?q=Megan%20Beetch"> Megan Beetch</a>, <a href="https://publications.waset.org/abstracts/search?q=Lucinda%20Kurzava"> Lucinda Kurzava</a>, <a href="https://publications.waset.org/abstracts/search?q=Hannah%20Buvala"> Hannah Buvala</a>, <a href="https://publications.waset.org/abstracts/search?q=Samer%20Gawrieh"> Samer Gawrieh</a>, <a href="https://publications.waset.org/abstracts/search?q=Suthat%20Liangpunsakul"> Suthat Liangpunsakul</a>, <a href="https://publications.waset.org/abstracts/search?q=Tracy%20Gonzalez"> Tracy Gonzalez</a>, <a href="https://publications.waset.org/abstracts/search?q=George%20McCabe"> George McCabe</a>, <a href="https://publications.waset.org/abstracts/search?q=Naga%20Chalasani"> Naga Chalasani</a>, <a href="https://publications.waset.org/abstracts/search?q=James%20M.%20Flanagan"> James M. Flanagan</a>, <a href="https://publications.waset.org/abstracts/search?q=Barbara%20Stefanska"> Barbara Stefanska</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatocellular carcinoma (HCC), the most prevalent type of primary liver cancer, is the second leading cause of cancer death worldwide. Late onset of clinical symptoms in HCC results in late diagnosis and poor disease outcome. Approximately 85% of individuals with HCC have underlying liver cirrhosis. However, not all cirrhotic patients develop cancer. Reliable early detection biomarkers that can distinguish cirrhotic patients who will develop cancer from those who will not are urgently needed and could increase the cure rate from 5% to 80%. We used Illumina-450K microarray to test whether blood DNA, an easily accessible source of DNA, bear site-specific changes in DNA methylation in response to HCC before diagnosis with conventional tools (pre-diagnostic). Top 11 differentially methylated sites were selected for validation by pyrosequencing. The diagnostic potential of the 11 pyrosequenced probes was tested in blood samples from a prospective cohort of cirrhotic patients. We identified 971 differentially methylated CpG sites in pre-diagnostic HCC cases as compared with healthy controls (P < 0.05, paired Wilcoxon test, ICC ≥ 0.5). Nearly 76% of differentially methylated CpG sites showed lower levels of methylation in cases vs. controls (P = 2.973E-11, Wilcoxon test). Classification of the CpG sites according to their location relative to CpG islands and transcription start site revealed that those hypomethylated loci are located in regulatory regions important for gene transcription such as CpG island shores, promoters, and 5’UTR at higher frequency than hypermethylated sites. Among 735 CpG sites hypomethylated in cases vs. controls, 482 sites were assigned to gene coding regions whereas 236 hypermethylated sites corresponded to 160 genes. Bioinformatics analysis using GO, KEGG and DAVID knowledgebase indicate that differentially methylated CpG sites are located in genes associated with functions that are essential for gene transcription, cell adhesion, cell migration, and regulation of signal transduction pathways. Taking into account the magnitude of the difference, statistical significance, location, and consistency across the majority of matched pairs case-control, we selected 11 CpG loci corresponding to 10 genes for further validation by pyrosequencing. We established that methylation of CpG sites within 5 out of those 10 genes distinguish cirrhotic patients who subsequently developed HCC from those who stayed cancer free (cirrhotic controls), demonstrating potential as biomarkers of early detection in populations at risk. The best predictive value was detected for CpGs located within BARD1 (AUC=0.70, asymptotic significance ˂0.01). Using an additive logistic regression model, we further showed that 9 CpG loci within those 5 genes, that were covered in pyrosequenced probes, constitute a panel with high diagnostic accuracy (AUC=0.887; 95% CI:0.80-0.98). The panel was able to distinguish pre-diagnostic cases from cirrhotic controls free of cancer with 88% sensitivity at 70% specificity. Using blood as a minimally invasive material and pyrosequencing as a straightforward quantitative method, the established biomarker panel has high potential to be developed into a routine clinical test after validation in larger cohorts. This study was supported by Showalter Trust, American Cancer Society (IRG#14-190-56), and Purdue Center for Cancer Research (P30 CA023168) granted to BS. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biomarker" title="biomarker">biomarker</a>, <a href="https://publications.waset.org/abstracts/search?q=DNA%20methylation" title=" DNA methylation"> DNA methylation</a>, <a href="https://publications.waset.org/abstracts/search?q=early%20detection" title=" early detection"> early detection</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatocellular%20carcinoma" title=" hepatocellular carcinoma"> hepatocellular carcinoma</a> </p> <a href="https://publications.waset.org/abstracts/56216/identification-of-a-panel-of-epigenetic-biomarkers-for-early-detection-of-hepatocellular-carcinoma-in-blood-of-individuals-with-liver-cirrhosis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/56216.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">304</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5581</span> The Gut Microbiome in Cirrhosis and Hepatocellular Carcinoma: Characterization of Disease-Related Microbial Signature and the Possible Impact of Life Style and Nutrition</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Lena%20Lapidot">Lena Lapidot</a>, <a href="https://publications.waset.org/abstracts/search?q=Amir%20Amnon"> Amir Amnon</a>, <a href="https://publications.waset.org/abstracts/search?q=Rita%20Nosenko"> Rita Nosenko</a>, <a href="https://publications.waset.org/abstracts/search?q=Veitsman%20Ella"> Veitsman Ella</a>, <a href="https://publications.waset.org/abstracts/search?q=Cohen-Ezra%20Oranit"> Cohen-Ezra Oranit</a>, <a href="https://publications.waset.org/abstracts/search?q=Davidov%20Yana"> Davidov Yana</a>, <a href="https://publications.waset.org/abstracts/search?q=Segev%20Shlomo"> Segev Shlomo</a>, <a href="https://publications.waset.org/abstracts/search?q=Koren%20Omry"> Koren Omry</a>, <a href="https://publications.waset.org/abstracts/search?q=Safran%20Michal"> Safran Michal</a>, <a href="https://publications.waset.org/abstracts/search?q=Ben-Ari%20Ziv"> Ben-Ari Ziv</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related mortality worldwide. Liver Cirrhosis is the main predisposing risk factor for the development of HCC. The factor(s) influencing disease progression from Cirrhosis to HCC remain unknown. Gut microbiota has recently emerged as a major player in different liver diseases, however its association with HCC is still a mystery. Moreover, there might be an important association between the gut microbiota, nutrition, life style and the progression of Cirrhosis and HCC. The aim of our study was to characterize the gut microbial signature in association with life style and nutrition of patients with Cirrhosis, HCC-Cirrhosis and healthy controls. Design: Stool samples were collected from 95 individuals (30 patients with HCC, 38 patients with Cirrhosis and 27 age, gender and BMI-matched healthy volunteers). All participants answered lifestyle and Food Frequency Questionnaires. 16S rRNA sequencing of fecal DNA was performed (MiSeq Illumina). Results: There was a significant decrease in alpha diversity in patients with Cirrhosis (qvalue=0.033) and in patients with HCC-Cirrhosis (qvalue=0.032) compared to healthy controls. The microbiota of patients with HCC-cirrhosis compared to patients with Cirrhosis, was characterized by a significant overrepresentation of Clostridium (pvalue=0.024) and CF231 (pvalue=0.010) and lower expression of Alphaproteobacteria (pvalue=0.039) and Verrucomicrobia (pvalue=0.036) in several taxonomic levels: Verrucomicrobiae, Verrucomicrobiales, Verrucomicrobiaceae and the genus Akkermansia (pvalue=0.039). Furthermore, we performed an analysis of predicted metabolic pathways (Kegg level 2) that resulted in a significant decrease in the diversity of metabolic pathways in patients with HCC-Cirrhosis (qvalue=0.015) compared to controls, one of which was amino acid metabolism. Furthermore, investigating the life style and nutrition habits of patients with HCC-Cirrhosis, we found significant correlations between intake of artificial sweeteners and Verrucomicrobia (qvalue=0.12), High sugar intake and Synergistetes (qvalue=0.021) and High BMI and the pathogen Campylobacter (qvalue=0.066). Furthermore, overweight in patients with HCC-Cirrhosis modified bacterial diversity (qvalue=0.023) and composition (qvalue=0.033). Conclusions: To the best of the our knowledge, we present the first report of the gut microbial composition in patients with HCC-Cirrhosis, compared with Cirrhotic patients and healthy controls. We have demonstrated in our study that there are significant differences in the gut microbiome of patients with HCC-cirrhosis compared to Cirrhotic patients and healthy controls. Our findings are even more pronounced because the significantly increased bacteria Clostridium and CF231 in HCC-Cirrhosis weren't influenced by diet and lifestyle, implying this change is due to the development of HCC. Further studies are needed to confirm these findings and assess causality. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Cirrhosis" title="Cirrhosis">Cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatocellular%20carcinoma" title=" Hepatocellular carcinoma"> Hepatocellular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=life%20style" title=" life style"> life style</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20disease" title=" liver disease"> liver disease</a>, <a href="https://publications.waset.org/abstracts/search?q=microbiome" title=" microbiome"> microbiome</a>, <a href="https://publications.waset.org/abstracts/search?q=nutrition" title=" nutrition"> nutrition</a> </p> <a href="https://publications.waset.org/abstracts/96178/the-gut-microbiome-in-cirrhosis-and-hepatocellular-carcinoma-characterization-of-disease-related-microbial-signature-and-the-possible-impact-of-life-style-and-nutrition" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/96178.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">129</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5580</span> Effects of Branched-Chain Amino Acid Supplementation on Sarcopenic Patients with Liver Cirrhosis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Deepak%20Nathiya1">Deepak Nathiya1</a>, <a href="https://publications.waset.org/abstracts/search?q=Ramesh%20Roop%20Rai"> Ramesh Roop Rai</a>, <a href="https://publications.waset.org/abstracts/search?q=Pratima%20Singh1"> Pratima Singh1</a>, <a href="https://publications.waset.org/abstracts/search?q=Preeti%20Raj1"> Preeti Raj1</a>, <a href="https://publications.waset.org/abstracts/search?q=Supriya%20Suman"> Supriya Suman</a>, <a href="https://publications.waset.org/abstracts/search?q=Balvir%20Singh%20Tomar"> Balvir Singh Tomar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Sarcopenia is a catabolic state in liver cirrhosis (LC), accelerated with a breakdown of skeletal muscle to release amino acids which adversely affects survival, health-related quality of life, and response to any underlying disease. The primary objective of the study was to investigate the long-term effect of branched-chain amino acids (BCAA) supplementations on parameters associated with improved prognosis in sarcopenic patients with LC, as well as to evaluate its impact on cirrhotic-related events. Methods: We carried out a 24 week, single-center, randomized, open-label, controlled, two cohort parallel-group intervention trial comparing the efficacy of BCAA against lactoalbumin (L-ALB) on 106 sarcopenic liver cirrhotics. The BCAA (intervention) group was treated with 7.2 g BCAA per whereas, the lactoalbumin group was also given 6.3 g of L-Albumin. The primary outcome was to assess the impact of BCAA on parameters of sarcopenia: muscle mass, muscle strength, and physical performance. The secondary outcomes were to study combined survival and maintenance of liver function changes in laboratory and clinical markers in the duration of six months. Results: Treatment with BCAA leads to significant improvement in sarcopenic parameters: muscle strength, muscle function, and muscle mass. The total cirrhotic-related complications and cumulative event-free survival occurred fewer in the BCAA group than in the L-ALB group. Prognostic markers also improved significantly in the study. Conclusion: The current clinical trial demonstrated that long-term BCAAs supplementation improved sarcopenia and prognostic markers in patients with advanced liver cirrhosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=sarcopenia" title="sarcopenia">sarcopenia</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20cirrhosis" title=" liver cirrhosis"> liver cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=BCAA" title=" BCAA"> BCAA</a>, <a href="https://publications.waset.org/abstracts/search?q=quality%20of%20life" title=" quality of life"> quality of life</a> </p> <a href="https://publications.waset.org/abstracts/136354/effects-of-branched-chain-amino-acid-supplementation-on-sarcopenic-patients-with-liver-cirrhosis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/136354.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">136</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5579</span> Development of a Novel Score for Early Detection of Hepatocellular Carcinoma in Patients with Hepatitis C Virus</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hatem%20A.%20El-Mezayen">Hatem A. El-Mezayen</a>, <a href="https://publications.waset.org/abstracts/search?q=Hossam%20Darwesh"> Hossam Darwesh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background/Aim: Hepatocellular carcinoma (HCC) is often diagnosed at advanced stage where effective therapies are lacking. Identification of new scoring system is needed to discriminate HCC patients from those with chronic liver disease. Based on the link between vascular endothelial growth factor (VEGF) and HCC progression, we aimed to develop a novel score based on combination of VEGF and routine laboratory tests for early prediction of HCC. Methods: VEGF was assayed for HCC group (123), liver cirrhosis group (210) and control group (50) by Enzyme Linked Immunosorbent Assay (ELISA). Data from all groups were retrospectively analyzed including α feto protein (AFP), international normalized ratio (INR), albumin and platelet count, transaminases, and age. Areas under ROC curve were used to develop the score. Results: A novel index named hepatocellular carcinoma-vascular endothelial growth factor score (HCC-VEGF score)=1.26 (numerical constant) + 0.05 ×AFP (U L-1)+0.038 × VEGF(ng ml-1)+0.004× INR –1.02 × Albumin (g l-1)–0.002 × Platelet count × 109 l-1 was developed. HCC-VEGF score produce area under ROC curve of 0.98 for discriminating HCC patients from liver cirrhosis with sensitivity of 91% and specificity of 82% at cut-off 4.4 (ie less than 4.4 considered cirrhosis and greater than 4.4 considered HCC). Conclusion: Hepatocellular carcinoma-VEGF score could replace AFP in HCC screening and follow up of cirrhotic patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatocellular%20carcinoma" title="Hepatocellular carcinoma">Hepatocellular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=cirrhosis" title=" cirrhosis"> cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=HCV" title=" HCV"> HCV</a>, <a href="https://publications.waset.org/abstracts/search?q=diagnosis" title=" diagnosis"> diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20markers" title=" tumor markers"> tumor markers</a> </p> <a href="https://publications.waset.org/abstracts/19155/development-of-a-novel-score-for-early-detection-of-hepatocellular-carcinoma-in-patients-with-hepatitis-c-virus" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/19155.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">321</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5578</span> Diagnostic Performance of Tumor Associated Trypsin Inhibitor in Early Detection of Hepatocellular Carcinoma in Patients with Hepatitis C Virus </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Aml%20M.%20El-Sharkawy">Aml M. El-Sharkawy</a>, <a href="https://publications.waset.org/abstracts/search?q=Hossam%20M.%20Darwesh"> Hossam M. Darwesh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Abstract— Background/Aim: Hepatocellular carcinoma (HCC) is often diagnosed at advanced stage where effective therapies are lacking. Identification of new scoring system is needed to discriminate HCC patients from those with chronic liver disease. Based on the link between tumor associated trypsin inhibitor (TATI) and HCC progression, we aimed to develop a novel score based on combination of TATI and routine laboratory tests for early prediction of HCC. Methods: TATI was assayed for HCC group (123), liver cirrhosis group (210) and control group (50) by Enzyme Linked Immunosorbent Assay (ELISA). Data from all groups were retrospectively analyzed including α feto protein (AFP), international normalized ratio (INR), albumin and platelet count, transaminases, and age. Areas under ROC curve were used to develop the score. Results: A novel index named hepatocellular carcinoma-vascular endothelial growth factor score (HCC-TATI score) = 3.1 (numerical constant) + 0.09 ×AFP (U L-1) + 0.067 × TATI (ng ml-1) + 0.16 × INR – 1.17 × Albumin (g l-1) – 0.032 × Platelet count × 109 l-1 was developed. HCC-TATI score produce area under ROC curve of 0.98 for discriminating HCC patients from liver cirrhosis with sensitivity of 91% and specificity of 82% at cut-off 6.5 (ie less than 6.5 considered cirrhosis and greater than 4.4 considered HCC). Conclusion: Hepatocellular carcinoma-TATI score could replace AFP in HCC screening and follow up of cirrhotic patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatocellular%20carcinoma" title="Hepatocellular carcinoma">Hepatocellular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=cirrhosis" title=" cirrhosis"> cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=HCV" title=" HCV"> HCV</a>, <a href="https://publications.waset.org/abstracts/search?q=diagnosis" title=" diagnosis"> diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=TATI" title=" TATI "> TATI </a> </p> <a href="https://publications.waset.org/abstracts/20583/diagnostic-performance-of-tumor-associated-trypsin-inhibitor-in-early-detection-of-hepatocellular-carcinoma-in-patients-with-hepatitis-c-virus" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20583.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">337</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5577</span> Mitochondrial DNA Copy Number in Egyptian Patients with Hepatitis C Virus Related Hepatocellular Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Doaa%20Hashad">Doaa Hashad</a>, <a href="https://publications.waset.org/abstracts/search?q=Amany%20Elyamany"> Amany Elyamany</a>, <a href="https://publications.waset.org/abstracts/search?q=Perihan%20Salem"> Perihan Salem</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Hepatitis C virus infection (HCV) constitutes a serious dilemma that has an impact on the health of millions of Egyptians. Hepatitis C virus related hepatocellular carcinoma (HCV-HCC) is a crucial consequence of HCV that represents the third cause of cancer-related deaths worldwide. Aim of the study: assess the use of mitochondrial DNA (mtDNA) content as a non-invasive molecular biomarker in hepatitis c virus related hepatocellular carcinoma (HCV-HCC). Methods: A total of 135 participants were enrolled in the study. Volunteers were assigned to one of three groups equally; a group of HCV related cirrhosis (HCV-cirrhosis), a group of HCV-HCC and a control group of age- and sex- matched healthy volunteers with no evidence of liver disease. mtDNA was determined using a quantitative real-time PCR technique. Results: mtDNA content was lowest in HCV-HCC cases. No statistically significant difference was observed between the group of HCV-cirrhosis and the control group as regards mtDNA level. HCC patients with multi-centric hepatic lesions had significantly lower mtDNA content. On using receiver operating characteristic curve analysis, a cutoff of 34 was assigned for mtDNA content to distinguish between HCV-HCC and HCV-cirrhosis patients who are not yet complicated by malignancy. Lower mtDNA was associated with greater HCC risk on using healthy controls, HCV-cirrhosis, or combining both groups as a reference group. Conclusions: mtDNA content might constitute a non-invasive molecular biomarker that reflects tumor burden in HCV-HCC cases and could be used as a predictor of HCC risk in patients of HCV-cirrhosis. In addition, the non significant difference of mtDNA level between HCV-cirrhosis patients and healthy controls could eliminate the grey zone created by the use of AFP in some cirrhotic patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=DNA%20copy%20number" title="DNA copy number">DNA copy number</a>, <a href="https://publications.waset.org/abstracts/search?q=HCC" title=" HCC"> HCC</a>, <a href="https://publications.waset.org/abstracts/search?q=HCV" title=" HCV"> HCV</a>, <a href="https://publications.waset.org/abstracts/search?q=mitochondrial" title=" mitochondrial"> mitochondrial</a> </p> <a href="https://publications.waset.org/abstracts/45827/mitochondrial-dna-copy-number-in-egyptian-patients-with-hepatitis-c-virus-related-hepatocellular-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/45827.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">326</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5576</span> Relationship Between Muscle Mass and Insulin Resistance in Cirrhotic Patients with Hepatitis B</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ey%C3%BCp%20S.%20Akbas">Eyüp S. Akbas</a>, <a href="https://publications.waset.org/abstracts/search?q=Betul%20Ayaz"> Betul Ayaz</a>, <a href="https://publications.waset.org/abstracts/search?q=Beyza%20S.%20Haksever"> Beyza S. Haksever</a>, <a href="https://publications.waset.org/abstracts/search?q=Sema%20Basat"> Sema Basat</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We aimed to evaluate the relationship between insulin resistance, muscle mass and muscle strength in patients with Hepatitis B virus-related cirrhosis. In our study, there were 65 patients with hepatitis B virus-related cirrhosis in Child A and B group and 65 healthy control individual. Control group was chosen between patients who admitted to the internal medicine clinic and had no pathological values in a routine examination. Muscle mass index was calculated with bioimpedance analysis for both groups to determine muscle strength and muscle mass. Handgrip strength, arm, and calf circumference were measured. In both groups, HOMA-IR was calculated to determine insulin resistance. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) value was detected 3,47±3,80 in the study group and 1,83±1,20 in control group. There were significant differences between the two groups in arm circumference, fasting insulin, fasting glucose, HOMA-IR, High-density lipoprotein (HDL) and total cholesterol parameters. The correlation coefficient between muscle mass and insulin resistance was statistically insignificant, especially in the study group. In healthy individuals group and all the groups, there wasn’t a correlation between muscle mass and insulin resistance. The upper limit for HOMA-IR was determined as 3,2. In control group, %78,9 of individuals were in HOMA-IR ( < 3.2) group and %21,1 of them were in ( ≥ 3,2) group. In study group, %68,3 of individuals were in HOMA-IR ( < 3,2) group and %31.7 were in HOMA-IR ( ≥ 3,2) group. In our study, we did not find a relationship between muscle mass and insulin resistance in patients with liver cirrhosis. In the study group, we detected a positive relationship between muscle mass, handgrip strength, and calf circumference. We did not find a relationship between insulin resistance and handgrip strength in our study. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cirrhosis" title="cirrhosis">cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title=" hepatitis B"> hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=Insulin%20resistance" title=" Insulin resistance"> Insulin resistance</a>, <a href="https://publications.waset.org/abstracts/search?q=muscle%20mass" title=" muscle mass"> muscle mass</a> </p> <a href="https://publications.waset.org/abstracts/104448/relationship-between-muscle-mass-and-insulin-resistance-in-cirrhotic-patients-with-hepatitis-b" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/104448.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5575</span> Role of von Willebrand Factor Antigen as Non-Invasive Biomarker for the Prediction of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20El%20Horri">Mohamed El Horri</a>, <a href="https://publications.waset.org/abstracts/search?q=Amine%20Mouden"> Amine Mouden</a>, <a href="https://publications.waset.org/abstracts/search?q=Reda%20Messaoudi"> Reda Messaoudi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Chekkal"> Mohamed Chekkal</a>, <a href="https://publications.waset.org/abstracts/search?q=Driss%20Benlaldj"> Driss Benlaldj</a>, <a href="https://publications.waset.org/abstracts/search?q=Malika%20Baghdadi"> Malika Baghdadi</a>, <a href="https://publications.waset.org/abstracts/search?q=Lahcene%20Benmahdi"> Lahcene Benmahdi</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatima%20Seghier"> Fatima Seghier</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background/aim: Recently, the Von Willebrand factor antigen (vWF-Ag)has been identified as a new marker of portal hypertension (PH) and its complications. Few studies talked about its role in the prediction of esophageal varices. VWF-Ag is considered a non-invasive approach, In order to avoid the endoscopic burden, cost, drawbacks, unpleasant and repeated examinations to the patients. In our study, we aimed to evaluate the ability of this marker in the prediction of another complication of portal hypertension, which is portal hypertensive gastropathy (PHG), the one that is diagnosed also by endoscopic tools. Patients and methods: It is about a prospective study, which include 124 cirrhotic patients with no history of bleeding who underwent screening endoscopy for PH-related complications like esophageal varices (EVs) and PHG. Routine biological tests were performed as well as the VWF-Ag testing by both ELFA and Immunoturbidimetric techniques. The diagnostic performance of our marker was assessed using sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and receiver operating characteristic curves. Results: 124 patients were enrolled in this study, with a mean age of 58 years [CI: 55 – 60 years] and a sex ratio of 1.17. Viral etiologies were found in 50% of patients. Screening endoscopy revealed the presence of PHG in 20.2% of cases, while for EVsthey were found in 83.1% of cases. VWF-Ag levels, were significantly increased in patients with PHG compared to those who have not: 441% [CI: 375 – 506], versus 279% [CI: 253 – 304], respectively (p <0.0001). Using the area under the receiver operating characteristic curve (AUC), vWF-Ag was a good predictor for the presence of PHG. With a value higher than 320% and an AUC of 0.824, VWF-Ag had an 84% sensitivity, 74% specificity, 44.7% positive predictive value, 94.8% negative predictive value, and 75.8% diagnostic accuracy. Conclusion: VWF-Ag is a good non-invasive low coast marker for excluding the presence of PHG in patients with liver cirrhosis. Using this marker as part of a selective screening strategy might reduce the need for endoscopic screening and the coast of the management of these kinds of patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=von%20willebrand%20factor" title="von willebrand factor">von willebrand factor</a>, <a href="https://publications.waset.org/abstracts/search?q=portal%20hypertensive%20gastropathy" title=" portal hypertensive gastropathy"> portal hypertensive gastropathy</a>, <a href="https://publications.waset.org/abstracts/search?q=prediction" title=" prediction"> prediction</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20cirrhosis" title=" liver cirrhosis"> liver cirrhosis</a> </p> <a href="https://publications.waset.org/abstracts/143425/role-of-von-willebrand-factor-antigen-as-non-invasive-biomarker-for-the-prediction-of-portal-hypertensive-gastropathy-in-patients-with-liver-cirrhosis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/143425.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">205</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5574</span> The Effectiveness of Probiotics in the Treatment of Minimal Hepatic Encephalopathy Among Patients with Cirrhosis: An Expanded Meta-Analysis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Erwin%20Geroleo">Erwin Geroleo</a>, <a href="https://publications.waset.org/abstracts/search?q=Higinio%20Mappala"> Higinio Mappala</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction Overt Hepatic Encephalopathy (OHE) is the most dreaded outcome of liver cirrhosis. Aside from the triggering factors which are already known to precipitate OHE, there is growing evidence that an altered gut microbiota profile (dysbiosis) can also trigger OHE. MHE is the mildest form of hepatic encephalopathy(HE), affecting about one-third of patients with cirrhosis, and close 80% of patients with cirrhosis and manifests as abnormalities in central nervous system function. Since these symptoms are subclinical most patients are not being treated to prevent OHE. The gut microbiota have been evaluated by several studies as a therapeutic option for MHE, especially in decreasing the levels of ammonia, thus preventing progression to OHE Objectives This study aims to evaluate the efficacy of probiotics in terms of reduction of ammonia levels in patient with minimal hepatic encephalopathies and to determine if Probiotics has role in the prevention of progression to overt hepatic encephalopathy in adult patients with minimal hepatic encephalopathy (MHE) Methods and Analysis The literature search strategy was restricted to human studies in adults subjects from 2004 to 2022. The Jadad Score Calculation was utilized in the assessment of the final studies included in this study. Eight (8) studies were included. Cochrane’s Revman Web, the Fixed Effects model and the Ztest were all used in the overall analysis of the outcomes. A p value of less than 0.0005 was statistically significant. Results. These results show that Probiotics significantly lowers the level of Ammonia in Cirrhotic patients with OHE. It also shows that the use of Probiotics significantly prevents the progression of MHE to OHE. The overall risk of bias graph indicates low risk of publication bias among the studies included in the meta-analysis. Main findings This research found that plasma ammonia concentration was lower among participants treated with probiotics (p<0.00001).) Ammonia level of the probiotics group is lower by 13.96 μmol/ on the average. Overall risk of developing overt hepatic encephalopathy in the probiotics group is shown to be decreased by 15% as compared to the placebo group Conclusion The analysis showed that compared with placebo, probiotics can decrease serum ammonia, may improve MHE and may prevent OHE. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=minimal%20hepatic%20encephalopathy" title="minimal hepatic encephalopathy">minimal hepatic encephalopathy</a>, <a href="https://publications.waset.org/abstracts/search?q=probiotics" title=" probiotics"> probiotics</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20cirrhosis" title=" liver cirrhosis"> liver cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=overt%20hepatic%20encephalopathy" title=" overt hepatic encephalopathy"> overt hepatic encephalopathy</a> </p> <a href="https://publications.waset.org/abstracts/185292/the-effectiveness-of-probiotics-in-the-treatment-of-minimal-hepatic-encephalopathy-among-patients-with-cirrhosis-an-expanded-meta-analysis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/185292.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">46</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5573</span> Gastrointestinal Disturbances in Postural Orthostatic Tachycardia Syndrome (POTS)</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Chandralekha%20Ashangari">Chandralekha Ashangari</a>, <a href="https://publications.waset.org/abstracts/search?q=Amer%20Suleman"> Amer Suleman</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Purpose: The Postural Orthostatic Tachycardia Syndrome (POTS) affects primarily young women. POTS is a form of dysautonomia that is estimated to impact between 1,000,000 and 3,000,000 Americans, and millions more around the world. POTS is a form of orthostatic intolerance that is associated with many Gastrointestinal disturbances. The aim of this study is to determine the Gastrointestinal disturbances in Postural Orthostatic Tachycardia Syndrome (POTS) patients.2. Methods: 249 patients referred to our clinic from January to November with POTS. Reviewed the medical records of 249 POTS patients and gastrointestinal symptoms. Results: however out of 249 patients, 226 patients are female (90.76%; average age 32.69), 23 patients are male (9.24%; average age 27.91) Data analysis: Out of 249 patients 189 patients (76%) had vomiting or nausea, 150 patients (60%) had irritable bowel syndrome, 128 patients (51%) had bloating, 125 patients (50%) had constipation , 80 patients (32%) had abdominal pain, 56 patients (22%) had delayed gastric emptying, 24 patients (10%) had lactose intolerance, 8 patients (3%) had Gastroesophageal reflux disease, 5 patients (2%) had Iron deficiency anemia, 6 patients (2%) had Peptic ulcer disease, 4 patients (2%) had Celiac Disease. Conclusion: Patients with POTS have a very high prevalence of gastrointestinal symptoms however the majority of abnormalities appear to be motility related. Motility testing should be performed be performed in POTS patients. The diagnostic yield of endoscopic procedures appears to be low. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=gastrointestinal%20disturbances" title="gastrointestinal disturbances">gastrointestinal disturbances</a>, <a href="https://publications.waset.org/abstracts/search?q=Postural%20Orthostatic%20Tachycardia%20Syndrome%20%28POTS%29" title=" Postural Orthostatic Tachycardia Syndrome (POTS)"> Postural Orthostatic Tachycardia Syndrome (POTS)</a>, <a href="https://publications.waset.org/abstracts/search?q=celiac%20disease" title=" celiac disease"> celiac disease</a>, <a href="https://publications.waset.org/abstracts/search?q=POTS%20patients" title=" POTS patients"> POTS patients</a> </p> <a href="https://publications.waset.org/abstracts/25781/gastrointestinal-disturbances-in-postural-orthostatic-tachycardia-syndrome-pots" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/25781.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">338</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5572</span> Malignant Ovarian Cancer Ascites Confers Platinum Chemoresistance to Ovarian Cancer Cells: A Combination Treatment with Crizotinib and 2 Hydroxyestradiol Restore Platinum Sensitivity</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yifat%20Koren%20Carmi">Yifat Koren Carmi</a>, <a href="https://publications.waset.org/abstracts/search?q=Abed%20Agbarya"> Abed Agbarya</a>, <a href="https://publications.waset.org/abstracts/search?q=Hazem%20Khamaisi"> Hazem Khamaisi</a>, <a href="https://publications.waset.org/abstracts/search?q=Raymond%20Farah"> Raymond Farah</a>, <a href="https://publications.waset.org/abstracts/search?q=Yelena%20Shechtman"> Yelena Shechtman</a>, <a href="https://publications.waset.org/abstracts/search?q=Roman%20Korobochka"> Roman Korobochka</a>, <a href="https://publications.waset.org/abstracts/search?q=Jacob%20Gopas"> Jacob Gopas</a>, <a href="https://publications.waset.org/abstracts/search?q=Jamal%20Mahajna"> Jamal Mahajna</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Ovarian cancer (OC), the second most common form of gynecological malignancy, has a poor prognosis and is frequently identified in its late stages. The recommended treatment for OC typically includes a platinum-based chemotherapy, like carboplatin. Nonetheless, OC treatment has proven challenging due to toxicity and development of acquired resistance to therapy. Chemoresistance is a significant obstacle to a long-lasting response in OC patients, believed to arise from alterations within the cancer cells as well as within the tumor microenvironments (TME). Malignant ascites is a presenting feature in more than one-third of OC patients. It serves as a reservoir for a complex mixture of soluble factors, metabolites, and cellular components, providing a pro-inflammatory and tumor-promoting microenvironment for the OC cells. Malignant ascites is also associated with metastasis and chemoresistance. In an attempt to elucidate the role of TME in chemoresistance of OC, we monitored the ability of soluble factors derived from ascites fluids to affect platinum sensitivity of OC cells. This research, compared ascites fluids from non-malignant cirrhotic patients to those from OC patients in terms of their ability to alter the platinum sensitivity of OC cells. Our findings indicated that exposure to OC ascites induces platinum chemoresistance on OC cells in 11 out of 13 cases (85%). In contrast, 75% of cirrhosis ascites (3 out of 4) failed to confer platinum chemoresistance to OC cells. Cytokine array analysis revealed that IL-6, and to a lesser extent HGF were enriched in OC ascites, whereas IL-22 was enriched in cirrhosis ascites. Pharmaceutical inhibitors that target the IL-6/JAK signaling pathway were mildly effective in overcoming the platinum chemoresistance induced by malignant ascites. In contrast, Crizotinib an HGF/c-MET inhibitor, and 2-hydroxyestradiol (2HE2) were effective in restoring platinum chemoresistance to OC. Our findings demonstrate the importance of OC ascites in supporting platinum chemoresistance as well as the potential of a combination therapy with Crizotinib and the estradiol metabolite 2HE2 to regain OC cells chemosensitivity. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ovarian%20cancer" title="ovarian cancer">ovarian cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=platinum%20chemoresistance" title=" platinum chemoresistance"> platinum chemoresistance</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant%20ascites" title=" malignant ascites"> malignant ascites</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20microenvironment" title=" tumor microenvironment"> tumor microenvironment</a>, <a href="https://publications.waset.org/abstracts/search?q=IL-6" title=" IL-6"> IL-6</a>, <a href="https://publications.waset.org/abstracts/search?q=2-hydroxyestradiol" title=" 2-hydroxyestradiol"> 2-hydroxyestradiol</a>, <a href="https://publications.waset.org/abstracts/search?q=HGF" title=" HGF"> HGF</a>, <a href="https://publications.waset.org/abstracts/search?q=crizotinib" title=" crizotinib"> crizotinib</a> </p> <a href="https://publications.waset.org/abstracts/170418/malignant-ovarian-cancer-ascites-confers-platinum-chemoresistance-to-ovarian-cancer-cells-a-combination-treatment-with-crizotinib-and-2-hydroxyestradiol-restore-platinum-sensitivity" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/170418.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">69</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5571</span> Systemic Factors, Intraocular Lens, and Ocular Abnormalities in Patients with Intraocular Lens Glistening at a Tertiary Hospital in Semarang</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Azmi%20Ilmi%20Aziz">Azmi Ilmi Aziz</a>, <a href="https://publications.waset.org/abstracts/search?q=Wisnu%20Sadasih"> Wisnu Sadasih</a>, <a href="https://publications.waset.org/abstracts/search?q=Rizal%20Fanany"> Rizal Fanany</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: This study describes systemic factors, intraocular lens (IOL), and ocular abnormalities in patients with IOL glistening at a tertiary hospital in Semarang. Methods: A retrospective, with a descriptive approach on patients with IOL glistening who visited the eye clinic between August 2019 to June 2023. Results: Twenty-five patients were examined; 11 patients (44%) had IOL glistening in their right eye, 4 patients (16%) in their left eye, and 10 patients (40%) in both eyes. The gender of patients consisted of 12 male patients (48%) and 13 female patients (52%). The median age of the patients was 68 years. The mean onset was 4.44 years after the first cataract surgery. Hypertension was found in 13 patients (52%), and diabetes was found in 9 patients (36%). Nine patients (36%) were identified with a foldable IOL with a closed loop design, and 1 patient (4%) with a PMMA IOL with an iris-fixated IOL design, while 15 other patients’ IOL were unrecorded. Glaucoma was found in 3 patients (12%). Conclusions: The result of this study showed that more than half of the patients were hypertensive, and some were glaucomatous, which had been discussed relevant in previous studies. Most IOL that could be identified was foldable IOL with a closed loop design. To our knowledge, the design of an IOL to glistening had never been explored. A longer study involving larger subjects is needed to better describe the systemic factors, IOL, and ocular abnormalities in patients with IOL glistening. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=glistening" title="glistening">glistening</a>, <a href="https://publications.waset.org/abstracts/search?q=intraocular%20lens" title=" intraocular lens"> intraocular lens</a>, <a href="https://publications.waset.org/abstracts/search?q=foldable%20IOL" title=" foldable IOL"> foldable IOL</a>, <a href="https://publications.waset.org/abstracts/search?q=PMMA%20IOL" title=" PMMA IOL"> PMMA IOL</a> </p> <a href="https://publications.waset.org/abstracts/172154/systemic-factors-intraocular-lens-and-ocular-abnormalities-in-patients-with-intraocular-lens-glistening-at-a-tertiary-hospital-in-semarang" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/172154.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">85</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5570</span> Use of Beta Blockers in Patients with Reactive Airway Disease and Concomitant Hypertension or Ischemic Heart Disease </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Bharti%20Chogtu%20Magazine">Bharti Chogtu Magazine</a>, <a href="https://publications.waset.org/abstracts/search?q=Dhanya%20Soodana%20Mohan"> Dhanya Soodana Mohan</a>, <a href="https://publications.waset.org/abstracts/search?q=Shruti%20Nair"> Shruti Nair</a>, <a href="https://publications.waset.org/abstracts/search?q=Tanwi%20Trushna"> Tanwi Trushna</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The study was undertaken to analyse the cardiovascular drugs being prescribed in patients with concomitant reactive airway disease and hypertension or ischemic heart diseases (IHD). Also, the effect of beta-blockers on respiratory symptoms in these patients was recorded. Data was collected from medical records of patients with reactive airway disease and concomitant hypertension and IHD. It included demographic details of the patients, diagnosis, drugs prescribed and the patient outcome regarding the exacerbation of asthma symptoms with intake of beta blockers. Medical records of 250 patients were analysed.13% of patients were prescribed beta-blockers. 12% of hypertensive patients, 16.6% of IHD patients and 20% of patients with concomitant hypertension and IHD were prescribed beta blockers. Of the 33 (13%) patients who were on beta-blockers, only 3 patients had an exacerbation of bronchial asthma symptoms. Cardioselective beta-blockers under supervision appear to be safe in patients with reactive airway disease and concomitant hypertension and IHD. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=beta%20blockers" title="beta blockers">beta blockers</a>, <a href="https://publications.waset.org/abstracts/search?q=hypertension" title=" hypertension"> hypertension</a>, <a href="https://publications.waset.org/abstracts/search?q=ischemic%20heart%20disease" title=" ischemic heart disease"> ischemic heart disease</a>, <a href="https://publications.waset.org/abstracts/search?q=asthma" title=" asthma"> asthma</a> </p> <a href="https://publications.waset.org/abstracts/1343/use-of-beta-blockers-in-patients-with-reactive-airway-disease-and-concomitant-hypertension-or-ischemic-heart-disease" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/1343.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">445</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5569</span> Study of Contrast Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Upper Egypt Experience</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ali%20Kassem">Ali Kassem</a>, <a href="https://publications.waset.org/abstracts/search?q=Sharf%20Eldeen-Shazly"> Sharf Eldeen-Shazly</a>, <a href="https://publications.waset.org/abstracts/search?q=Alshemaa%20Lotfy"> Alshemaa Lotfy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Contrast-induced nephropathy (CIN) has been the third leading cause of hospital-acquired renal failure. Patients with cardiac diseases are particularly at risk especially with repeated injections of contrast media. CIN is generally defined as an increase in serum creatinine concentration of > 0.5 mg/dL or 25% above baseline within 48 hours after contrast administration. Aim of work: To examine the frequency of CIN for patients undergoing cardiac catheterization at Sohag University Hospital (Upper Egypt) and to identify possible risk factors for CIN in these patients. Material and methods: The study included 104 patients with mean age 56.11 ±10.03, 64(61.5%) are males while 40(38.5%) are females. 44(42.3%) patients are diabetics, 43(41%) patients are hypertensive, 6(5.7%) patients have congestive heart failure, 69(66.3%) patients on statins, 74 (71.2 %) are on ACEIs or ARBs, 19(15.4%) are on metformin, 6 (5.8%) are on NSAIDs, 30(28.8%) are on diuretics. RESULTS: Patients were classified at the end of the study into two groups: Group A: Included 91 patients who did not develop CIN. Group B: Included 13 patients who developed CIN, of which serum creatinine raised > 0.5mg/dl in 6 patients and raised > 25% from the baseline after the procedure in 13 patients. The overall incidence of CIN was 12.5%. CIN increased with older age. There was an increase in the incidence of CIN in diabetic versus non-diabetic patients (20.5% and 6.7%) respectively. (p< 0.03). There was a highly significant increase in the incidence of CIN in patients with CHF versus those without CHF (100% and 71%) respectively, (P<0001). Patients on diuretics showed a significant increase in the incidence of CIN representing 61.5% of all patients who developed CIN. Conclusion: Older patients, diabetic patients, patients with CHF and patients on diuretics have higher risk of developing CIN during coronary catheterization and should receive reno-protective measures before contrast exposure. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cardiac%20diseases" title="cardiac diseases">cardiac diseases</a>, <a href="https://publications.waset.org/abstracts/search?q=contrast-induced%20nephropathy" title=" contrast-induced nephropathy"> contrast-induced nephropathy</a>, <a href="https://publications.waset.org/abstracts/search?q=coronary%20catheterization" title=" coronary catheterization"> coronary catheterization</a>, <a href="https://publications.waset.org/abstracts/search?q=CIN" title=" CIN"> CIN</a> </p> <a href="https://publications.waset.org/abstracts/32783/study-of-contrast-induced-nephropathy-in-patients-undergoing-cardiac-catheterization-upper-egypt-experience" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/32783.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">313</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5568</span> Study on Quality of Life among Patients Undergoing Hemodialysis in National Kidney Centre, Banasthali, Kathmandu</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tara%20Gurung">Tara Gurung</a>, <a href="https://publications.waset.org/abstracts/search?q=Suprina%20Prajapati"> Suprina Prajapati</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Health and well being of people is a crucial for accomplishing sustainable development goals of any country. The present study focuses on quality of life of patients undergoing hemodialysis. Hemodialysis is a life sustaining treatment for patients with end stage renal disease (ESRD). Hemodialysis can bring about significant impairment in health related quality of life (HRQOL). The purpose of this study was to assess the quality of life of hemodialysis patients undergoing hemodialysis. A descriptive cross-sectional research design was utilized in total 100 samples using random sampling technique. The findings revealed that the total quality of life of the patients was 30.41±3.99 out of 100. The total physical component score was statistically significant with education status of the patients where p value for t test was 0.03 (p=0.03) and occupation of the patients where p value for the ANOVA test was 0.007 (p=0.007). The study recommended that it would be better if awareness programs regarding chronic kidney disease and life style modification in hemodialysis patients is given to the patients so that it would help patients to maintain the HRQOL. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=health%20and%20well%20bing" title="health and well bing">health and well bing</a>, <a href="https://publications.waset.org/abstracts/search?q=hemodialysis" title=" hemodialysis"> hemodialysis</a>, <a href="https://publications.waset.org/abstracts/search?q=patients%20quality%20of%20life" title=" patients quality of life "> patients quality of life </a> </p> <a href="https://publications.waset.org/abstracts/117690/study-on-quality-of-life-among-patients-undergoing-hemodialysis-in-national-kidney-centre-banasthali-kathmandu" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/117690.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">143</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5567</span> Characterization of Coronary Artery Obstruction and Related Findings in Ischemic Heart Patients Using Cardiac Scintigraphy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yousif%20Mohamed%20Y.%20Abdallah">Yousif Mohamed Y. Abdallah</a>, <a href="https://publications.waset.org/abstracts/search?q=Eltayeb%20Wagi%20Allah%20Eltayeb"> Eltayeb Wagi Allah Eltayeb</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20E.%20Gar-elnabi"> Mohamed E. Gar-elnabi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Ahmed%20Ali"> Mohamed Ahmed Ali </a> </p> <p class="card-text"><strong>Abstract:</strong></p> To characterize coronary artery obstruction and related findings in ischemic heart patients using cardiac scintigraphy for the identification of myocardial ischemia, 146 patients were studied at basal conditions and also asked for fasting after night till the intravenous injection of the radiopharmaceutical. After the injection time about 15 to 20 minutes, the patient should eat a fatty meal and chocolate for the good excretion of the gall bladder, to evaluate the performance and regional wall motion of the left ventricle (LV). The results showed that the body mass index percentage in this sample was in range of 43.05 to 61.05. The number of patients who were catheter candidates were 56 with 43% and the patients that were not candidate to cathode were 74 patients with 57% of all patients. For the group of patients where type of ischemia was assessed, 29.5% of patients had reversible posterior and inferior wall, 15.1% of patients had fixed large from apex to base, 9.6% of patients had mild basal inferior wall, 4.8 % of patients had mild anterior wall, 6.2% of patients had antro-septal and 34.9% of patients had moderate ischemia. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=myocardial%20ischemia" title="myocardial ischemia">myocardial ischemia</a>, <a href="https://publications.waset.org/abstracts/search?q=myocardial%20scintigraphy" title=" myocardial scintigraphy"> myocardial scintigraphy</a>, <a href="https://publications.waset.org/abstracts/search?q=contrast%20ventriculography" title=" contrast ventriculography"> contrast ventriculography</a>, <a href="https://publications.waset.org/abstracts/search?q=coronary%20artery%20obstruction" title=" coronary artery obstruction"> coronary artery obstruction</a> </p> <a href="https://publications.waset.org/abstracts/13957/characterization-of-coronary-artery-obstruction-and-related-findings-in-ischemic-heart-patients-using-cardiac-scintigraphy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13957.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">585</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5566</span> Procalcitonin and Other Biomarkers in Sepsis Patients: A Prospective Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Neda%20Valizadeh">Neda Valizadeh</a>, <a href="https://publications.waset.org/abstracts/search?q=Soudabeh%20Shafiee%20Ardestani"> Soudabeh Shafiee Ardestani</a>, <a href="https://publications.waset.org/abstracts/search?q=Arvin%20Najafi"> Arvin Najafi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objectives: The aim of this study is to evaluate the association of mid-regional pro-atrial natriuretic peptide (MRproANP), procalcitonin (PCT), proendothelin-1 (proET-1) levels with sepsis severity in Emergency ward patients. Materials and Methods: We assessed the predictive value of MRproANP, PCT, copeptin, and proET-1 in early sepsis among patients referring to the emergency ward with a suspected sepsis. Results-132 patients were enrolled in this study. 45 (34%) patients had a final diagnosis of sepsis. A higher percentage of patients with definite sepsis had systemic inflammatory response syndrome (SIRS) criteria at initial visit in comparison with no-sepsis patients (P<0.05) and were admitted to the hospital (P<0.05). PCT levels were higher in sepsis patients [P<0.05]. There was no significant differences for MRproANP or proET-1 in sepsis patients (P=0.47). Conclusion: A combination of SIRS criteria and PCT levels is beneficial for the early sepsis diagnosis in emergency ward patients with a suspicious infection disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=emergency" title="emergency">emergency</a>, <a href="https://publications.waset.org/abstracts/search?q=prolactin" title=" prolactin"> prolactin</a>, <a href="https://publications.waset.org/abstracts/search?q=sepsis" title=" sepsis"> sepsis</a>, <a href="https://publications.waset.org/abstracts/search?q=biomarkers" title=" biomarkers"> biomarkers</a> </p> <a href="https://publications.waset.org/abstracts/18189/procalcitonin-and-other-biomarkers-in-sepsis-patients-a-prospective-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18189.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">439</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5565</span> Role of von Willebrand Factor and ADAMTS13 In The Prediction of Thrombotic Complications In Patients With COVID-19</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nataliya%20V.%20Dolgushina">Nataliya V. Dolgushina</a>, <a href="https://publications.waset.org/abstracts/search?q=Elena%20A.%20Gorodnova"> Elena A. Gorodnova</a>, <a href="https://publications.waset.org/abstracts/search?q=Olga%20S.%20Beznoshenco"> Olga S. Beznoshenco</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrey%20Yu%20Romanov"> Andrey Yu Romanov</a>, <a href="https://publications.waset.org/abstracts/search?q=Irina%20V.%20Menzhinskaya"> Irina V. Menzhinskaya</a>, <a href="https://publications.waset.org/abstracts/search?q=Lyubov%20V.%20Krechetova"> Lyubov V. Krechetova</a>, <a href="https://publications.waset.org/abstracts/search?q=Gennady%20T.%20Suchich"> Gennady T. Suchich</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In patients with COVID-19, generalized hypercoagulability can lead to the development of severe coagulopathy. This event is accompanied by the development of a pronounced inflammatory reaction. The observational prospective study included 39 patients with mild COVID-19 and 102 patients with moderate and severe COVID-19. Patients were then stratified into groups depending on the risk of venous thromboembolism. vWF to ADAMTS-13 concentrations and activity ratios were significantly higher in patients with a high venous thromboembolism risks in patients with moderate and severe forms COVID-19. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ADAMTS-13" title="ADAMTS-13">ADAMTS-13</a>, <a href="https://publications.waset.org/abstracts/search?q=COVID-19" title=" COVID-19"> COVID-19</a>, <a href="https://publications.waset.org/abstracts/search?q=hypercoagulation" title=" hypercoagulation"> hypercoagulation</a>, <a href="https://publications.waset.org/abstracts/search?q=thrombosis" title=" thrombosis"> thrombosis</a>, <a href="https://publications.waset.org/abstracts/search?q=von%20Willebrand%20factor" title=" von Willebrand factor"> von Willebrand factor</a> </p> <a href="https://publications.waset.org/abstracts/150818/role-of-von-willebrand-factor-and-adamts13-in-the-prediction-of-thrombotic-complications-in-patients-with-covid-19" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/150818.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">89</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5564</span> Investigation of Chronic Drug Use Due to Chronic Diseases in Patients Admitted to Emergency Department</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Behcet%20Al">Behcet Al</a>, <a href="https://publications.waset.org/abstracts/search?q=%C5%9Eener%20Cindoruk"> Şener Cindoruk</a>, <a href="https://publications.waset.org/abstracts/search?q=Suat%20Zengin"> Suat Zengin</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehmet%20Murat%20Oktay"> Mehmet Murat Oktay</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehmet%20Mustafa%20Sunar"> Mehmet Mustafa Sunar</a>, <a href="https://publications.waset.org/abstracts/search?q=Hatice%20Eroglu"> Hatice Eroglu</a>, <a href="https://publications.waset.org/abstracts/search?q=Cuma%20Yildirim"> Cuma Yildirim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objective: In present study we aimed to investigate the chronic drug use due to chronic diseases in patients admitted to emergency department. Materials-Methods: 144 patients who applied to emergency department (ED) of medicine school of Gaziantep University between June 2013 and September 2013 with chronic diseases and use chronic drugs were included. Information about drugs used by patients were recorded. Results: Of patients, half were male, half were female, and the mean age was 58 years. The first three common diseases were diabetes mellitus, hypertension and coronary artery diseases. Of patients, %79.2 knew their illness. Fifty patients began to use drug within three months, 36 patient began to use within the last one year. While 42 patients brought all of their drugs with themselves, 17 patients brought along a portion of drugs. While three patients stopped their medication completely, 125 patients received medication on a regular basis. Fifty-two patient described the drugs with names, 13 patients described with their colors, 3 patients described by grammes, 45 patients described with the size of the tablet and 13 patients could not describe the drugs. Ninety-two patients explained which kind of drugs were used for each diseases, 17 patient explained partly, and 35 patients had no idea. Hundred patients received medication by themselves, 44 patients medications were giving by their relatives and med carers. Of medications, 140 were written by doctors directly, three medication were given by pharmacist; and one patient bought the drug by himself. For 11 patients the drugs were not harmonious to their diseases. Fifty-one patients admitted to the ED two times within last week, and 73 admitted two times within last month. Conclusion: The majority of patients with chronic diseases and use chronic drugs know their diseases and use the drugs in order, but do not have enough information about their medication. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20disease" title="chronic disease">chronic disease</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20use" title=" drug use"> drug use</a>, <a href="https://publications.waset.org/abstracts/search?q=emergency%20department" title=" emergency department"> emergency department</a>, <a href="https://publications.waset.org/abstracts/search?q=medication" title=" medication"> medication</a> </p> <a href="https://publications.waset.org/abstracts/12353/investigation-of-chronic-drug-use-due-to-chronic-diseases-in-patients-admitted-to-emergency-department" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/12353.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">463</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5563</span> C-Reactive Protein in Patients with Type 2 Diabetes Mellitus</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Athar%20Hussain%20Memon">Athar Hussain Memon</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objectives: We tried to determine the frequency of raised C-reactive protein (CRP) in patients with type 2 diabetes mellitus. Patients and Methods: This cross-sectional descriptive study of six months study was conducted at Liaquat University Hospital Hyderabad from March 2013 to August 2013. All diabetic patients of ≥35 years age of either gender for >01 year duration visited at OPD were evaluated for C-reactive protein and their glycemic status by hemoglobin A1c. The data was analyzed in SPSS and the frequency and percentage were calculated. Results: During six month study period, total 100 diabetic patients were evaluated for C-reactive protein. The majority of patients were from urban areas 75/100 (75%). The mean ±SD for age of patients with diabetes mellitus was 51.63±7.82. The mean age ±SD of patient with raised CRP was 53±7.21. The mean ±SD for HbA1c in patients with raised CRP is 9.55±1.73. The mean random blood sugar level in patients with raised CRP was 247.42 ± 6.62. The majority of subjects were of 50-69 years of age group with female predominance (p=0.01) while the CRP was raised in 70 (70%) patients in relation to age (p=0.02) and gender (p=0.01), respectively. Both HbA1c and CRP were raised in 64.9% (p=0.04) in patients with type 2 diabetes mellitus. The mean ±SD of CRP was 5.8±1.21 while for male and female individuals with raised CRP was 3.52±1.22 and 5.7±1.63, respectively. Conclusions: The raised CRP was observed in patients with type 2 diabetes mellitus. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=diabetes%20mellitus" title="diabetes mellitus">diabetes mellitus</a>, <a href="https://publications.waset.org/abstracts/search?q=C-reactive%20protein" title=" C-reactive protein"> C-reactive protein</a>, <a href="https://publications.waset.org/abstracts/search?q=hemoglobin%20A1c" title=" hemoglobin A1c"> hemoglobin A1c</a>, <a href="https://publications.waset.org/abstracts/search?q=diabetes%20and%20metabolism" title=" diabetes and metabolism"> diabetes and metabolism</a> </p> <a href="https://publications.waset.org/abstracts/24244/c-reactive-protein-in-patients-with-type-2-diabetes-mellitus" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/24244.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">415</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5562</span> Hypoglycemic Coma in Elderly Patients with Diabetes mellitus</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=D.%20Furuya">D. Furuya</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Ryujin"> H. Ryujin</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Takahira"> S. Takahira</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Sekine"> Y. Sekine</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Oya"> Y. Oya</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Sonoda"> K. Sonoda</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Ogawa"> H. Ogawa</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Nomura"> Y. Nomura</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20Maruyama"> R. Maruyama</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Kim"> H. Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=T.%20Kudo"> T. Kudo</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Nakano"> A. Nakano</a>, <a href="https://publications.waset.org/abstracts/search?q=T.%20Saruta"> T. Saruta</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Sugita"> S. Sugita</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Nemoto"> M. Nemoto</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20Tanahashi"> N. Tanahashi </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: To study the clinical characteristics of hypoglycemic coma in adult patients with type 1 or type 2 diabetes mellitus (DM). Methods: Participants in this retrospective study comprised 91 patients (54 men, 37 women; mean age ± standard deviation, 71.5 ± 12.6 years; range, 42-97 years) brought to our emergency department by ambulance with disturbance of consciousness in the 7 years from April 2007 to March 2014. Patients with hypoglycemia caused by alcoholic ketoacidosis, nutrition disorder, malignancies and psychological disorder were excluded. Results: Patients with type 1 (8 of 91) or type 2 DM (83 of 91) were analyzed. Mean blood sugar level was 31.6 ± 10.4 in all patients. A sulfonylurea (SU) was more commonly used in elderly (>75 years old; n=44)(70.5%) than in younger patients (36.2%, p < 0.05). Cases showing prolonged unconsciousness (range, 1 hour to 21 days; n=30) included many (p < 0.05) patients with dementia (13.3%; 0.5% without dementia) and fewer (p < 0.05) patients with type 1 DM (0%; 13.1% in type 2 DM). Specialists for DM (n=33) used SU less often (24.2%) than general physicians (69.0%, p < 0.05). Conclusion: In cases of hypoglycemic coma, SU was frequently used in elderly patients with DM. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hypoglycemic%20coma" title="hypoglycemic coma">hypoglycemic coma</a>, <a href="https://publications.waset.org/abstracts/search?q=Diabetes%20mellitus" title=" Diabetes mellitus"> Diabetes mellitus</a>, <a href="https://publications.waset.org/abstracts/search?q=unconsciousness" title=" unconsciousness"> unconsciousness</a>, <a href="https://publications.waset.org/abstracts/search?q=elderly%20patients" title=" elderly patients"> elderly patients</a> </p> <a href="https://publications.waset.org/abstracts/20274/hypoglycemic-coma-in-elderly-patients-with-diabetes-mellitus" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20274.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">490</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5561</span> Operating Model of Obstructive Sleep Apnea Patients in North Karelia Central Hospital </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=L.%20Korpinen">L. Korpinen</a>, <a href="https://publications.waset.org/abstracts/search?q=T.%20Kava"> T. Kava</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Salmi"> I. Salmi </a> </p> <p class="card-text"><strong>Abstract:</strong></p> This study aimed to describe the operating model of obstructive sleep apnea. Due to the large number of patients, the role of nurses in the diagnosis and treatment of sleep apnea was important. Pulmonary physicians met only a minority of the patients. The sleep apnea study in 2018 included about 800 patients, of which about 28% were normal and 180 patients were classified as severe (apnea-hypopnea index [AHI] over 30). The operating model has proven to be workable and appropriate. The patients understand well that they may not be referred to a pulmonary doctor. However, specialized medical follow-up on professional drivers continues every year. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=sleep" title="sleep">sleep</a>, <a href="https://publications.waset.org/abstracts/search?q=apnea%20patient" title=" apnea patient"> apnea patient</a>, <a href="https://publications.waset.org/abstracts/search?q=operating%20model" title=" operating model"> operating model</a>, <a href="https://publications.waset.org/abstracts/search?q=hospital" title=" hospital"> hospital</a> </p> <a href="https://publications.waset.org/abstracts/111322/operating-model-of-obstructive-sleep-apnea-patients-in-north-karelia-central-hospital" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/111322.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">132</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5560</span> Clinical Features of Acute Aortic Dissection Patients Initially Diagnosed with ST-Segment Elevation Myocardial Infarction</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Min%20Jee%20Lee">Min Jee Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Young%20Sun%20Park"> Young Sun Park</a>, <a href="https://publications.waset.org/abstracts/search?q=Shin%20Ahn"> Shin Ahn</a>, <a href="https://publications.waset.org/abstracts/search?q=Chang%20Hwan%20Sohn"> Chang Hwan Sohn</a>, <a href="https://publications.waset.org/abstracts/search?q=Dong%20Woo%20Seo"> Dong Woo Seo</a>, <a href="https://publications.waset.org/abstracts/search?q=Jae%20Ho%20Lee"> Jae Ho Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Yoon%20Seon%20Lee"> Yoon Seon Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Kyung%20Soo%20Lim"> Kyung Soo Lim</a>, <a href="https://publications.waset.org/abstracts/search?q=Won%20Young%20Kim"> Won Young Kim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Acute myocardial infarction (AMI) concomitant with acute aortic syndrome (AAS) is rare but prompt recognition of concomitant AAS is crucial, especially in patients with ST-segment elevation myocardial infarction (STEMI) because misdiagnosis with early thrombolytic or anticoagulant treatment may result in catastrophic consequences. Objectives: This study investigated the clinical features of patients of STEMI concomitant with AAS that may lead to the diagnostic clue. Method: Between 1 January 2010 and 31 December 2014, 22 patients who were the initial diagnosis of acute coronary syndrome (AMI and unstable angina) and AAS (aortic dissection, intramural hematoma and ruptured thoracic aneurysm) in our emergency department were reviewed. Among these, we excluded 10 patients who were transferred from other hospital and 4 patients with non-STEMI, leaving a total of 8 patients of STEMI concomitant with AAS for analysis. Result: The mean age of study patients was 57.5±16.31 years and five patients were Standford type A and three patients were type B aortic dissection. Six patients had ST-segment elevation in anterior leads and two patients had in inferior leads. Most of the patients had acute onset, severe chest pain but no patients had dissecting nature chest pain. Serum troponin I was elevated in three patients but all patients had D-dimer elevation. Aortic regurgitation or regional wall motion abnormality was founded in four patients. However, widened mediastinum was seen in all study patients. Conclusion: When patients with STEMI have elevated D-dimer and widened mediastinum, concomitant AAS may have to be suspected. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=aortic%20dissection" title="aortic dissection">aortic dissection</a>, <a href="https://publications.waset.org/abstracts/search?q=myocardial%20infarction" title=" myocardial infarction"> myocardial infarction</a>, <a href="https://publications.waset.org/abstracts/search?q=ST-segment" title=" ST-segment"> ST-segment</a>, <a href="https://publications.waset.org/abstracts/search?q=d-dimer" title=" d-dimer"> d-dimer</a> </p> <a href="https://publications.waset.org/abstracts/37573/clinical-features-of-acute-aortic-dissection-patients-initially-diagnosed-with-st-segment-elevation-myocardial-infarction" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/37573.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">398</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5559</span> Memory Types in Hemodialysis (HD) Patients; A Study Based on Hemodialysis Duration, Zahedan: South East of Iran</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Behnoush%20Sabayan">Behnoush Sabayan</a>, <a href="https://publications.waset.org/abstracts/search?q=Ali%20Alidadi"> Ali Alidadi</a>, <a href="https://publications.waset.org/abstracts/search?q=Saeid%20Ebarhimi"> Saeid Ebarhimi</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20M.%20Bakhshani"> N. M. Bakhshani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hemodialysis (HD) patients are at a high risk of atherosclerotic and vascular disease; also little information is available for the HD impact on brain structure of these patients. We studied the brain abnormalities in HD patients. The aim of this study was to investigate the effect of long term HD on brain structure of HD patients. Non-contrast MRI was used to evaluate imaging findings. Our study included 80 HD patients of whom 39 had less than six months of HD and 41 patients had a history of HD more than six months. The population had a mean age of 51.60 years old and 27.5% were female. According to study, HD patients who have been hemodialyzed for a long time (median time of HD was up to 4 years) had small vessel ischemia than the HD patients who underwent HD for a shorter term, which the median time was 3 to 5 months. Most of the small vessel ischemia was located in pre-ventricular, subcortical and white matter (1.33± .471, 1.23± .420 and 1.39±.490). However, the other brain damages like: central pons abnormality, global brain atrophy, thinning of corpus callosum and frontal lobe atrophy were found (P<0.01). The present study demonstrated that HD patients who were under HD for a longer time had small vessel ischemia and we conclude that this small vessel ischemia might be a causative mechanism of brain atrophy in chronic hemodialysis patients. However, additional researches are needed in this area. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hemodialysis%20Patients" title="Hemodialysis Patients">Hemodialysis Patients</a>, <a href="https://publications.waset.org/abstracts/search?q=Duration%20of%20Hemodialysis" title=" Duration of Hemodialysis"> Duration of Hemodialysis</a>, <a href="https://publications.waset.org/abstracts/search?q=MRI" title=" MRI"> MRI</a>, <a href="https://publications.waset.org/abstracts/search?q=Zahedan" title=" Zahedan"> Zahedan</a> </p> <a href="https://publications.waset.org/abstracts/83278/memory-types-in-hemodialysis-hd-patients-a-study-based-on-hemodialysis-duration-zahedan-south-east-of-iran" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/83278.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">213</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=186">186</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=187">187</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=cirrhotic%20patients&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>